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Abstract
Background: Diabetes is known to impair the number and function of endothelial progenitor cells in the
circulation, causing structural and functional alterations in the micro- and macro-vasculature. The aim of this study
was to identify early diabetes-related changes in the expression of genes that have been reported to be closely
involved in endothelial progenitor cell migration and function.
Methods: Based on review of current literature, this study examined the expression level of 35 genes that are
known to be involved in endothelial progenitor cell migration and function in magnetically sorted Lin−/VEGF-R2+
endothelial progenitor cells obtained from the bone marrow of Akita mice in the early stages of diabetes (18
weeks) using RT-PCR and Western blotting. We used the Shapiro-Wilk and D’Agostino & Pearson Omnibus tests to
assess normality. Differences between groups were evaluated by Student’s t-test for normally distributed data
(including Welch correction in cases of unequal variances) or Mann–Whitney test for not normally distributed data.
Results: We observed a significant increase in the number of Lin−/VEGF-R2+ endothelial progenitor cells within the
bone marrow in diabetic mice compared with non-diabetic mice. Two genes, SDF-1 and SELE, were significantly
differentially expressed in diabetic Lin−/VEGF-R2+ endothelial progenitor cells and six other genes, CAV1, eNOS,
CLDN5, NANOG, OCLN and BDNF, showed very low levels of expression in diabetic Lin−/VEGF-R2+ progenitor cells.
Conclusion: Low SDF-1 expression may contribute to the dysfunctional mobilization of bone marrow Lin−/VEGF-R2+
endothelial progenitor cells, which may contribute to microvascular injury in early diabetes.
Keywords: Diabetes, Endothelial progenitor cells, Diabetic vasculopathies, Molecular pathology, SDF-1, Lin−/VEGF-R2+
EPCs, Cardiovascular pathology, Retinopathy
Background
The inner lining of blood vessels, the endothelium, is
made up of a single layer of endothelial cells (ECs) [1],
which acts as a barrier between the blood and the sur-
rounding tissue. It prevents inflammatory cell infiltration,
modulates vascular tone and controls smooth muscle cell
proliferation [2-4]. Damage to the endothelium can be
repaired by proliferation and migration of nearby mature
ECs [5,6], which have limited regenerative capacity [7,8].
Endothelial progenitor cells (EPCs) originating from the
bone marrow (BM) can migrate to the peripheral blood
(PB) [9,10] and repair injured endothelium [11,12]. These
EPCs play an important role in regenerating the endo-
thelium through migration, proliferation, differentiation
and by secreting pro-angiogenic cytokines [13]. EPCs ex-
press a range of cell surface markers, among them stem
cell markers (CD34, CD133) and endothelial markers
(CD146, vWF, VEGF-R2) [14,15]. As no single or unique
marker for EPCs has been identified, researchers use a
range of markers and phenotypical properties to define
them [16,17]. Regardless of this lack of accuracy, the term
“EPC” is used and it is acknowledged that “EPC” refers to
a heterogeneous population of cells rather than a single
population [17-19].
Diabetes mellitus, characterized by chronic hypergly-
cemia [20], is a metabolic condition that strongly affects
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EPCs. Diabetic patients have reduced numbers of EPCs
[21,22] in the PB and the function of such EPCs isolated
from PB with respect to proliferation, tube formation
and adhesion is impaired [23,24]. Most importantly, EPCs
from diabetic individual are less competent in repairing
vascular injuries [23,25,26]. Not only impaired function
but also reduced mobilization from the BM to the PB has
been documented [22,24] in diabetic patients. Both the de-
creased number of EPCs and their impaired function have
been proposed to be involved in the pathogenesis of vas-
cular complications in diabetes [21,23,27].
Since most studies to elucidate molecular mechanisms
of EPC impairment in diabetes have been conducted in
EPCs isolated from the PB in humans with a long history
of diabetes, little is known about the changes occurring
in EPCs located within the BM in the early stages of dia-
betes. A subset of BM derived EPCs, which are phenotyp-
ically characterized as Lin−/VEGF-R2+ cells were recently
described [28]. These Lin−/VEGF-R2+ endothelial pro-
genitor cells (abbreviated as Lin−/VEGF-R2+ EPCs in this
study) have typical properties of EPCs such as formation
of cobblestone-shaped colonies, Dil-acLDL uptake, lectin
binding, expression of typical EPC markers such as VEGF-
R2 and CD34, lack of expression of CD31, CD45, CD14
and CD115 and incorporation into damaged blood vessels
in vivo [28] .
We have recently shown [28] that BM derived Lin−/
VEGF-R2+ cells isolated from diabetic mice showed nei-
ther functional differences nor reduced proliferative cap-
acity compared with such cells isolated from non-diabetic
mice. However, we found a distinct defect in mobilization
of Lin−/VEGF-R2+ cells from BM to the PB in diabetic
mice. To explore the molecular mechanisms underlying
this defect in mobilization of BM Lin−/VEGF-R2+ EPCs in
spontaneously diabetic mice, the current study aimed to
evaluate differential gene expression of 35 genes that were
reported to be closely involved in Lin−/VEGF-R2+ EPC
mobilization and function.
Methods
Animals
All animal studies were conducted in accordance with the
New South Wales Animals Act (1985). Approval was issued
by The University of Sydney Animal Ethics Committee
(Approval number: K17/9-2007/3/4664). All efforts were
made to minimize animals suffering. The animals, Ins2Akita
mice (Akita mice), were obtained from The Jackson
Laboratory (Bar Harbor, ME, USA). The Akita mouse
carries a dominant point mutation in the Insulin 2 gene on
chromosome 7 resulting in the development of diabetes at
approximately 4 weeks after birth [29] with almost 100%
penetrance [30]. As female mice develop diabetes more
slowly and less stably compared with males [29], only male
mice heterozygous for the Ins2Akita allele (diabetic group)
as well as male mice homozygous for the wild type Ins2 al-
lele (non-diabetic mice) were used in this study. Presence
of the Ins2Akita allele or the wild type Ins2 gene was con-
firmed by RFLP analysis [30]. Once diabetes was estab-
lished (blood glucose level > 13.3mmol/l [31]), mice were
monitored weekly for changes in body weight and blood
glucose levels for 18 weeks. The blood glucose level was
measured using Accu-Chek Performa (Roche, Germany).
No supplemental insulin was given. Only mice having
blood glucose levels consistently ≥ 13.3 mmol/l were
used in this study. Eight diabetic and 8 non-diabetic mice
were used.
BM collection
After euthanizing mice with CO2, the femorae and tibiae
of both legs were immediately excised and the diaphyses
flushed using a 25g needle and 8 ml of IMag™ buffer
(BD, Cat no. 552362). The collected cells were placed on
ice. After centrifugation (400 rcf, 5 min), the cell pellet
was resuspended in 2 ml red cell lysing buffer (Sigma,
Cat no. R7757). After 5 min incubation and centrifuga-
tion (400 rcf, 5 min), the cell pellet was resuspended
in 10 ml of IMag™ buffer and washed twice. Cells were
eventually filtered using a 40 μm nylon cell strainer (BD,
Cat no. 352340), centrifuged (400 rcf, 5 min) and re-
suspended in 2 ml of IMag™ buffer. After cell count-
ing (TC10, BioRad) and viability assessment using the
trypan blue exclusion assay, cells were placed on ice for
the isolation of Lin−/VEGF-R2+ cells.
Immunomagnetic bead separation of BM Lin−/VEGF-R2+
endothelial progenitor cells
BM cells were incubated with NA/LE rat anti-mouse
CD16/CD32 (Fc-block, 1 μg/106 cells, BD, Cat no. 553140)
for 15 min. After Fc-block, BM cells were incubated
with a solution containing an APC mouse lineage antibody
cocktail (BD, Cat no. 558074) and a FITC rat anti-mouse
Flk-1/VEGF-R2 antibody (BD, Cat no. 560680). After 20
min incubation, cells were centrifuged (400 rcf, 5 min)
and washed twice using cold IMag™ buffer. Cells were in-
cubated with magnetic beads for 30 min at 4°C (APC
magnetic particles-DM; BD, Cat no. 557932). The APC
mouse lineage cocktail was used to separate Lin+ cells
from the whole of bone marrow cells, i.e. hematopoietic
lineage cells such as T lymphocyes, B lymphocytes, mono-
cytes/macrophages, granulocytes, and erythrocytes cells
containing surface antigens such as CD3e, CD11, CD45R/
B220, Ly-76, Ly-6G and Ly-6C. The Lin+ depletion
was conducted using a Dynal MPC-S magnetic separator
(Invitrogen, Cat no. 12020D). The Lin− fraction was fur-
ther incubated with anti-FITC beads (Miltenyi Biotec,
Cat no. 130-048-701) for 30 min at 4°C. The fraction
of Lin−/VEGF-R2+ EPCs was obtained via a positive
selection step using the magnetic separator. For RNA
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isolation, fractions of both Lin+ and the Lin−/VEGF-R2+
cells were collected, washed in PBS and centrifuged. Cell
pellets were re-suspended in 100 μl of RNA later solution
(Qiagen, Cat no. 76104) and snap-frozen in liquid nitro-
gen. Cells destined to undergo protein analysis were dir-
ectly snap-frozen and stored at −80°C for further use.
Group design
Four experimental groups were established: 1) Lin+ cells
from non-diabetic animals, 2) Lin+ cells from diabetic
animals, 3) Lin−/VEGF-R2+ cells from non-diabetic ani-
mals and 4) Lin−/VEGF-R2+ cells from diabetic animals.
The Lin+ cells were used as an internal reference to
identify differential gene expression occurring not exclu-
sively in Lin−/VEGF-R2+ cells. This setup allowed us to
distinguish differential gene expression which specifically
occurred in diabetic BM derived Lin−/VEGF-R2+ EPCs
from that which may also occur in other phenotypes of
BM cells. Hence, only significant changes in gene expres-
sion observed in diabetic vs. non-diabetic Lin−/VEGF-R2+
EPCs that did not occur in the Lin+ population were con-
sidered in the final analysis.
RNA isolation
RNA isolation was performed at room temperature
using the RNeasy Mini Kit (Qiagen, Cat no. 74104) ac-
cording to the manufacturer’s instructions. Isolated
RNA was snap-frozen and stored at −80°C for further use.
RNA concentration was measured using a Nanodrop 1000
(Nanodrop Products, DE, USA), integrity was assessed
using the BioRad Experion automated electrophoresis sys-
tem (BioRad, CA, USA) on a RNA StdSens Chip (BioRad
Cat no. 700–7159).
Reverse transcription
Reverse transcription was done using the iScript cDNA
synthesis kit (BioRad, Cat no. 170–8890). In brief, 4 μl
of 5× iScript reaction buffer, 1 μl iScript reverse tran-
scriptase, 500 ng RNA and water up to a total reaction
volume of 20 μl were mixed. The reverse transcription
program was designed as follows: 25°C for 5 min, 42°C for
60 min, 85°C for 5 min followed by 4°C at a hold step. Re-
actions were performed in a PCR machine (HBPX220,
Hybaid, UK). The finial 20 μl cDNA product was diluted
into 160 μl total volume using MQ water.
Real time PCR
Primer sequences for RT-PCR were obtained from
http://pga.mgh.harvard.edu/primerbank and from http://
primerdepot.nci.nih.gov/. In silico analyses were performed
to identify the amplicon size and suitability of the primer
pairs. An overview of genes tested and primers used
is shown in Additional file 1: Table S1. All primers
had a melting temperature of approximately 61°C and
were tested before RT-PCR using gel electrophoresis to
visualize amplicons. For testing primers, a total reaction
volume of 10 μl comprised of 5 μl Super Mix (SsoFast
EvaGreen Supermix, BioRad, Cat no. 172–5200), 1 μl of 4
μM forward and reverse primer mixture, 1 μl of cDNA
and 3 μl water. PCR steps used were similar to the RT-
PCR program used later: 95°C for 30 s, 40 cycles of 95°C
for 5 s then 60°C for 20 s. This was followed by a melting
curve step starting from 65°C to 95°C each step lasting
30s, ramp rate was 0.5°C/s. PCR products were analyzed
in 2% agarose (in TBE buffer) gels to verify amplicon size.
RT-PCR was performed on a LightCycler 480 (Roche,
Switzerland) using 384 well plates. Each group included
seven individual samples, each individual sample was rep-
licated once (technical replicate). The program was as fol-
lows: 95°C for 5 min, 40 cycles of 95°C for 10 s, 60°C for
20 s and 72°C for 20 s. Ramp rate was 4.8°C/s. Each well
contained 5 μl Express Sybr Green (Invitrogen, Cat no.
10000162), 0.5 μl water, 0.5 μl of 4 μM forward and re-
verse primer mixture and 4 μl of the diluted sample
cDNA. Mouse glyceraldehyde-3-phosphate dehydrogenase
(mGAPDH) [32,33] and 18S ribosomal RNA (18srRNA)
were used as reference genes. The two reference genes
were chosen using “BESTKEEPER” software (http://rest-
2009.gene-quantification.info/), taking into account the
information that there are no significant differences in
mGAPDH and 18srRNA. Since progenitor cells from bone
marrow were used, it was not clear whether one single
chosen reference gene would be expressed. GAPDH con-
tent may be altered in animal models of diabetes, however,
not all mouse strains are affected and in C57/BL6 mice
mGAPDH has been successfully used as reference gene
[32,33]. CT-values were computed using the 2nd order
derivation method, CT values ≥ 35 were excluded from
the analysis. Data analysis was performed using the RT2
profiler PCR array data analysis available on http://pcrda-
taanalysis.sabiosciences.com/pcr/arrayanalysis.php.
Protein isolation and Western blot
For Western blot analysis, 8 samples from each group
were used. The isolated cells were incubated and lysed for
30 min at 4°C in RIPA buffer (Sigma, Cat no. 127K6009)
containing protease inhibitor (Complete mini; Roche, Cat
no. 046931240010; 1 tablet per 10 ml RIPA buffer). Buffer
volume was adjusted to a concentration of 5 × 104 cells/μl
RIPA buffer. The lysed cells were centrifuged at 12,000 rcf
for 20 min at 4°C. The supernatant containing the protein
was aliquoted (26 μl) and stored at −20°C for further use.
Gel-electrophoresis to separate proteins according to
their size was done using 2,2-Bis(hydroxymethyl)-2, 2′,
2″-nitrilotriethanol (Bis-Tris) polyacrylamide gels with a
gradient from 4 to 12% under denaturing conditions (Nupage,
Invitrogen, Cat no. NP0335) using 2-(N-morpholino) ethane-
sulfonic acid sodium dodecyl sulfate (MES-SDS, Invitrogen,
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Cat No NP0002) as running buffer. Before loading the gel
wells, 26 μl protein sample, 10 μl loading buffer (Invitrogen,
Cat no. NP0007), 4 μl 500 mM DL-dithiothreitol (DTT;
Sigma, Cat no. D9779-10G) were mixed and kept at 70°C
for 10 min to denature the protein and after this kept on
ice for 5 min. After gel-electrophoresis, gels were removed
from the running chamber and placed on a 0.2 μm polyvi-
nyl difluoride (PVDF) membrane (Invitrogen, Cat no.
LC2002). The protein transfer was done using a wet trans-
fer system (BioRad Mini Trans-Blot, Cat no. 170–3930).
After the transfer, the PVDF membranes were washed for
5 min using water and then for 10 min using TBST: tris
(hydroxymethyl) aminomethane (TRIS) buffer, 150 mM
sodium chloride and 0.1% polyoxyethylene (20) sorbitan
monolaurate (TWEEN 20). A blocking step followed using
5% bovine serum albumin (BSA, Sigma, Cat no. 9418) in
TBST and incubating the PVDF membrane for 1 h at
room temperature. After washing the membrane twice in
TBST, the incubation with the primary antibody (SDF-1;
1:2000, Abcam, Cat no. ab25117) in TBST and 1% BSA
followed over night at 4°C. The next day the primary anti-
body solution was removed and the PVDF membrane
washed 3 times in TBST for 5 min. Exposure to the second-
ary antibody HRP-goat anti-rabbit IgG (H + L) conjugate
(horseradish peroxidase coupled; Zymed, Cat no. 81–6120)
followed for 2 h at room temperature. After washing 3×
for 5 min with TBST, the PVDF membrane was washed
twice with TBS and then incubated for 5 min with the che-
moluminescent agent (Millipore, Cat no. WBKLS0500).
Immediately after this, the chemoluminescent agent was
removed and the PVDF membrane was analyzed using a
digital imaging system (G:Box, Syngene, MD, USA). After
recording, the PVDF membrane was stripped of the anti-
bodies by incubating for 5 min at room temperature with a
Western blot stipping buffer (Thermo Scientific, Cat no.
46430). After washing the membrane in TBST, the incuba-
tion with the next primary antibody followed (E-Selectin,
1:2000, Abcam, Cat no. ab18981) and the procedure of
overnight incubation, secondary antibody incubation and
imaging was repeated. To evaluate differences in protein
levels, chemiluminosity readings of target proteins were di-
vided by chemiluminosity readings of reference proteins
from the same sample. Relative expression levels were
compared between diabetic and non-diabetic samples.
Statistics
Data are presented as mean ± standard deviation (SD) for
normally distributed data and as mean [interquartile range]
when non-normally distributed. Normality was assessed
using the Shapiro-Wilk test and the D’Agostino and Pearson
Omnibus normality tests. Differences in variances of nor-
mally distributed data were assessed using Levene’s test.
Differences between two groups were either assessed using
a student’s t-test (normally distributed data) including
Welch correction in case of unequal variances or Mann–
Whitney test (non-normally distributed data). Statistical
significance was defined as p < 0.05.
Results
Animal body weight and blood glucose levels
All heterozygous male Akita mice had blood glucose
levels ≥13.3 mmol/l from 4 weeks of age. At the time of
analysis, mice 22 weeks of age had a body weight of
36.0 ± 2.8 g and 24.5 ± 2.8 g for non-diabetic and dia-
betic mice respectively (p < 0.0001). Mean blood glucose
at 22 weeks of age was 8.9 [7.8-10.2] mmol/l in non-
diabetic and 33.4 [28.2-33.4] mmol/l in diabetic animals
(p < 0.0001, Figure 1).
Cell numbers in the bone marrow
Overall an absolute number of 3.33 [2.93-3.98] × 107 nu-
cleated cells were isolated from the BM of each mouse.
On average, 5.4 ± 2.3% of the BM nucleated cells were
Lin−/VEGF-R2+ cells and 82.3 ± 4.4% were Lin+. The
remaining Lin−/VEGF-R2− cells made up ~12%. While in
non-diabetic mice 9.37 [8.61-10.75] × 105 cells/g body
Figure 1 Body weight and blood glucose levels. Body weight (A) and blood glucose levels (B) in non-diabetic (control) and diabetic mice at
22 weeks of age (18 weeks of diabetes). Asterisk (*) denotes statistical significance (p < 0.05).
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weight were isolated, from diabetic mice 1.37 [1.10-1.69] ×
106 cells/g body weight could be obtained (p < 0.0001).
Similarly, the number of Lin−/VEGF-R2+ EPCs in the BM
was significantly greater in diabetic than non-diabetic ani-
mals after adjusting for body weight: 7.56 [6.20-8.37] ×
104 cells/g body weight vs. 4.24 [3.44-5.08] × 104 cells/g
body weight (p < 0.0001). There were 1.17 [0.94-1.39] ×
106 Lin+ cells/g body weight in diabetic animals and 7.58
[6.85-8.71] × 105 Lin+ cells/g body weight in non-diabetic
animals (p = 0.074).
RNA quality and quantity
From the Lin+ fraction, 253.5 ± 117.3 ng/μl RNA could
be isolated from diabetic animals and 234.0 ± 98.1 ng/μl
RNA from non-diabetic animals (p = 0.64). The Lin−/
VEGF-R2+ EPCs fraction yielded 135.3 ± 68.1 ng/μl RNA
from diabetic mice and 88.0 ± 53.3 ng/μl RNA from non-
diabetic mice (p = 0.05). The integrity of RNA, expressed
as RNA quality indicator (RQI) was ≥7 in all samples, in-
dicating intact RNA (see BioRad tech note 5761 Rev B;
http://www.biorad.com).
Gene expression changes
Of the 35 genes studied, HSPD1, SDF-1 and SELE showed
significant changes between non-diabetic and diabetic
Lin−/VEGF-R2+ EPCs. While SDF-1 was down regu-
lated about 0.3-fold, SELE was up regulated 2.4-fold
in diabetic compared to non-diabetic Lin−/VEGF-R2+
EPCs. No significant changes in SDF-1 and SELE expres-
sion were found between non-diabetic and diabetic Lin+
cells, whereas HSPD1 showed a significant change and a
similar fold-change in the diabetic Lin+ cells compared to
the non-diabetic Lin+ cells. Therefore, we considered that
the differential expression of SDF-1 and SELE genes was
specific for Lin−/VEGF-R2+ EPCs. There was a small non-
significant increase in the expression of CXCR4 between
non-diabetic and diabetic Lin−/VEGF-R2+ EPCs. HIF1A
and Tie2 were significantly differentially expressed be-
tween diabetic Lin+ cells and non-diabetic Lin+ cells only.
Unfortunately, no analysis could be performed for 6 genes
including CAV1, eNOS, CLDN5, NANOG, OCLN and
BDNF due to CT values ≥35. It is accepted that CT values
of 35 or higher represent detection of single molecules in
the sample, these readings are therefore considered noise,
hence are not reliable expression values and should not be
analysed [34-36]. A detailed overview of the results of the
gene-expression analysis is shown in Table 1.
Protein level changes
As only SDF-1 and SELE showed specific changes in Lin−/
VEGF-R2+ EPCs in diabetic animals compared with non-
diabetics, validation of differential expression at the pro-
tein level was performed only for these two genes. For the
two genes studied, Western blot showed that only SDF-1
was significantly down regulated in diabetic BM Lin−/
VEGF-R2+ EPCs, while no significant change was found
for SELE in Western blot analysis (see Figures 2 and 3,
Table 2).
Discussion
The present study analyzed differential gene expression
in freshly isolated Lin−/VEGF-R2+ EPCs obtained from
murine BM in the early stages of diabetes (18 weeks). A
total of 35 genes that were previously reported to be in-
volved in EPC mobilization and EPC function [15,37-57]
were tested to see whether the reported diabetes-related
changes observed mainly in EPCs from PB of diabetic
humans could also be found in BM-derived progenitor
cells from mice with early diabetes. There were three main
findings. Firstly, the number of Lin−/VEGF-R2+ EPCs/g
body weight within the BM was significantly higher in
diabetic than non-diabetic animals. Secondly, SDF-1
and SELE were significantly differentially expressed in
diabetic Lin−/VEGF-R2+ EPCs but not in diabetic BM
Lin+ cells, indicating that the differential expression of
SDF-1 and SELE are specific for BM Lin−/VEGF-R2+
EPCs in diabetic mice. The changes observed at the
mRNA level were confirmed by Western blot analysis only
for SDF-1. Thirdly, 6 genes including CAV1, eNOS,
CLDN5, NANOG, OCLN and BDNF showed such low
levels of expression that no comparison could be made.
These results demonstrate differential expression of
one gene (SDF-1) of BM derived progenitor cells in
diabetic mice that may contribute to their dysfunc-
tional mobilization from the BM to the PB and that
Lin−/VEGF-R2+ EPCs may be very early progenitor cells.
The observation of higher numbers of Lin−/VEGF-R2+
EPCs/g body weight found in diabetic mice compared
with non-diabetic animals is consistent with previous
findings in a streptozotocin-induced diabetic mouse model
[28]. This may indicate that in early stages of diabetes pro-
genitors are “trapped” inside the BM. The reduced expres-
sion of SDF-1, one of the key factors involved in EPC
mobilization may partially contribute to this finding. Based
on the current results, it seems in early diabetes mainly
impacts mobilization rather than cell genuine progenitor
cell function, which would tally reports that reduction of
EPCs in the PB in patients with diabetes is not necessarily
coupled to an impaired function [58].
The ability of EPCs to produce SDF-1 has been shown
in EPCs isolated from the BM [59] as well as in those
isolated from the PB [60]. As EPCs express both SDF-1
and its receptor (CXCR4) [61], an autocrine/paracrine
regulation loop for SDF-1 [62] within EPCs has been
proposed. The functional interaction between SDF-1 and
CXCR4 in EPCs within the BM is still unclear. However,
recent studies indicate that the interaction between
SDF-1 ligand and its CXCR4 receptor appears to play
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important roles in both mobilization of EPCs from the
BM to the PB and EPC maturation [62,63]. Our finding
of down regulation of SDF-1 in diabetic BM Lin−/VEGF-
R2+ EPCs indicates that reduced expression of SDF-1
may contribute to the impaired mobilization of Lin−/
VEGF-R2+ EPCs observed in diabetic mice. A recent
study proposed that high glucose leads to reduced ex-
pression of HIF1α which in turn results in a lower level
of SDF-1 expression [64]. Others have reported that ad-
vanced glycation end products impair SDF-1 production
in endothelial progenitor cells in a dose dependent man-
ner [65].
Table 1 Overview of the RT-PCR analysis
Diabetic lin+ vs. Non-diabetic lin+ Diabetic EPC vs. Non-diabetic EPC
Gene Fold-change 95% CI of fold-change p-value Fold-change 95% CI of fold-change p-value
AKT 1.04 (0.84, 1.24) 0.7622 0.34 (0.00, 1.16) 0.9111
BDNF - - - - - -
CASP9 0.77 (0.54, 1.00) 0.1172 0.79 (0.55, 1.03) 0.1151
CAV1 - - - - - -
CDH5 0.84 (0.62, 1.07) 0.1977 0.81 (0.30, 1.32) 0.8824
CLDN5 - - - - - -
CXCR4 0.73 (0.50, 0.96) 0.0800 0.80 (0.54, 1.06) 0.1993
eNOS - - - - - -
EPO 1.06 (0.62, 1.51) 0.8700 1.16 (0.68, 1.64) 0.5543
EPO-R 1.21 (0.80, 1.61) 0.1860 0.90 (0.68, 1.13) 0.5005
FGF1 0.73 (0.08, 1.38) 0.3329 0.76 (0.17, 1.35) 0.2288
FN1 1.24 (0.72, 1.77) 0.5181 1.62 (0.94, 2.29) 0.0628
GATA2 0.73 (0.47, 0.99) 0.1182 0.62 (0.32, 0.93) 0.0534
HIF1A 0.52 (0.35, 0.69) 0.0019 0.78 (0.35, 1.20) 0.3114
HOXA9 1.29 (0.90, 1.68) 0.0890 0.65 (0.00, 1.72) 0.4628
HSPD1 0.51 (0.35, 0.68) 0.0005 0.59 (0.32, 0.86) 0.0371
ICAM1 0.95 (0.67, 1.22) 0.6373 0.70 (0.39, 1.01) 0.0997
IGF1 0.89 (0.18, 1.60) 0.6833 1.02 (0.14, 1.90) 0.9718
IL11 1.48 (0.74, 2.23) 0.1445 1.70 (0.64, 2.77) 0.1572
IL6 1.04 (0.84, 1.25) 0.7680 1.33 (0.90, 1.75) 0.1526
MMP2 0.88 (0.38, 1.38) 0.5561 0.88 (0.35, 1.41) 0.5012
MMP9 0.78 (0.40, 1.17) 0.4096 1.05 (0.76, 1.34) 0.6447
NANOG - - - - - -
OCLN - - - - - -
P53 0.92 (0.79, 1.05) 0.2973 1.05 (0.89, 1.22) 0.6169
PIK3R1 0.80 (0.56, 1.04) 0.2263 0.81 (0.60, 1.02) 0.1029
PKC 1.04 (0.77, 1.30) 0.7644 1.08 (0.82, 1.33) 0.6184
PTPN11 0.94 (0.77, 1.11) 0.5361 1.14 (0.96, 1.32) 0.1280
SDF-1 0.48 (0.16, 0.80) 0.0891 0.32 (0.04, 0.60) 0.0149
SELE 1.92 (0.24, 3.60) 0.1913 2.41 (1.42, 3.39) 0.0005
Tie2 2.28 (0.89, 3.68) 0.0059 1.22 (0.69, 1.75) 0.5184
VCAM1 1.22 (0.85, 1.60) 0.2085 0.62 (0.25, 0.98) 0.0687
VEGFA 1.08 (0.00, 3.69) 0.9400 1.12 (0.83, 1.41) 0.4433
VEGFR1 1.03 (0.70, 1.35) 0.8699 0.59 (0.25, 0.93) 0.0729
VEGFR2 0.56 (0.26, 0.86) 0.0721 0.55 (0.14, 0.96) 0.2806
The table indicates the changes in diabetic vs non-diabetic. Down regulated genes have a fold-change < 1 and up regulated genes have a fold-change > 1. Only
SDF-1 and SELE show significant changes in the Lin−/VEGF-R2+ EPCs while showing no significant changes in the Lin+ group. HIF1A shows significant change in
the Lin+ group but not in the Lin−/VEGF-R2+ EPCs group.
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Consistent with these findings of impaired mobilisa-
tion of Lin−/VEGF-R2+ EPCs and SDF-1 downregulation
are recent reports that SDF-1 is crucial in mobilizing
progenitor cells [66] and that direct application of SDF-1
to rats with myocardial infarction reduced the infarction
size, probably by stimulating migration of progenitor
cells to the heart thereby altering postinfarction vascular
remodeling [67]. These recent findings together with the
results of the current study emphasize the importance of
an early SDF-1 downregulation on cell mobilisation. The
interactions between HIF1α expression, regulation of SDF-
1 expression and mobilization of BM-EPCs in diabetic vas-
culopathies warrant further research.
Expression of SELE (CD62E) in circulating EPCs has
been described [68,69]. Several recent studies suggest that
SELE expression is a sign of EC or EPC activation [70-72]
Figure 2 Relative expression of SDF-1 and SELE in relation to GAPDH expression (reference gene) in Lin−/VEGF-R2+ EPCs and Lin+ cells.
The central bar indicates the mean, whiskers indicates ± 1 SD interval. Asterisk (*) denotes statistical significance (p < 0.05).
Figure 3 Western blot membrane imaging. Protein expression of
SDF-1 and SELE in Lin-/VEGF-R2+ EPCs and Lin+ cells isolated from
the BM of non-diabetic and diabetic mice. Specific SDF-1 and SELE
signal was detected by probing blots with anti-SDF-1 and anti-SELE
antibodies. Two representative samples of a total of eight biological
replicates per group are shown. GAPDH was used as loading control.
Densitometry analysis was processed to evaluate the expression of
SDF-1 and SELE. While Lin+ cells do not show obvious changes,
Lin−/VEGF-R2+ EPCs show changes regarding SDF-1 and SELE
expression, though only changes observed in SDF-1 are
statistically significant.
Table 2 Overview of the Western blot analysis
Lin+ Lin−/VEGF-R2+
Diabetic vs Non-diabetic Diabetic vs Non-diabetic
Fold-change p-value Fold-change p-value
SELE 1.06 0.676 1.69 0.2136
SDF-1 0.86 0.1645 0.45 0.0114
Only SDF-1 shows significant changes on the protein level while the
up-regulation of SELE is not significant.
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because unstimulated BM-derived EPCs do not express
SELE [73]. The up-regulation of SELE in Lin−/VEGF-R2+
EPCs in diabetic BM may be attributed to increased pro-
duction of inflammatory cytokines such as interleukin 1
and tumor necrosis factors caused by the diabetic condi-
tion [74].
Many studies have linked the EPC function to eNOS,
which is considered one of the cardinal enzymes involved
in mobilization of EPCs from the BM to the PB as well as
maintaining the normal function of EPCs in physiological
conditions [41,42,75-77]. In the present study we found
that eNOS expression in BM Lin−/VEGF-R2+ EPCs was
very low. This is in accordance with a number of observa-
tions showing that eNOS expression is absent in imma-
ture EPCs but its level is increased when EPCs become
more mature [43,44,77]. The low level of eNOS as well
as CAV1, CLDN5, NANOG, OCLN and BDNF expression
in BM Lin−/VEGF-R2+ EPCs may indicate that the Lin−/
VEGF-R2+ population consists mainly of immature or very
early progenitor cells.
Mobilization of progenitor cells from the BM is com-
plex and is based on the interplay of different factors.
Results from testing 35 genes for differential expression
can explain only partially observed effects of diabetes on
BM progenitor cells, which can be considered as a limi-
tation of this study. Further studies may choose broader
approaches. Another limitation is that gene expression
was tested only at one time point and hence no informa-
tion on the timing of the SDF-1 expression changes can
be monitored or whether other genes may be differentially
expressed in the course of diabetes impacting mobilization
and/or function.
Conclusions
Overall, the present study indicates that a short period
of diabetes is sufficient to trap a significant number of
Lin−/VEGF-R2+ EPCs in the BM and to induce reduced
expression of SDF-1, which could be one of the predomin-
ant reasons to account for the dysfunctional mobilization
of Lin−/VEGF-R2+ EPCs from the BM to PB. Future re-
search on regulation of SDF-1 expression in BM-EPCs
may lead to novel therapeutic strategies for treatment of
early diabetic vasculopathies.
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